From barons some comparaisons The company's Grail business had $10 million in March sales of its Galleri blood test, which looks for telltale genetic fragments to give early warning on dozens of different cancers. Grail lost $172 million on March operations. Illumina stuck to its guidance that Grail sales this year can reach $70 million to $90 million.
The CEO has said that cancer screening could become the biggest market for sequencing.
Antitrust regulators in the U.S. and Europe want to unwind Illumina's $8 billion acquisition of Grail, which the governments believe will stifle competitive efforts in cancer early-detection by rivals like Guardant Health (GH) and Exact Sciences (EXAS). Their labs rely on Illumina sequencing systems. Illumina is fighting those antitrust cases and says it will appeal any adverse initial rulings.
glta